Search

News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia

Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.

Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?

What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from the broader spectrum of neuromyelitis optica (NMOSD) in Czechia? And which risk factors pertain to this specific population? Data from the ReMuS registry, summarized in an article by Czech authors recently published in the journal Multiple Sclerosis and Related Disorders, revealed this and more. We offer a unique insight into the issue of COVID-19 in these patients in our conditions.

Source: Multiple Sclerosis 28. 7. 2021

News Clinical Results of the Pinnacle Acetabular System: Data from the UK Joint Replacement Registry

The Pinnacle Acetabular System has been available on the market for nearly two decades. Since then, it has been implanted in numerous healthcare facilities worldwide. Clinical outcomes of the acetabular system were evaluated by analyzing data from the National Joint Replacement Registry of England, Wales, Northern Ireland, and the Isle of Man.

Source: Large Joints 22. 4. 2020

News Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results

Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of patients with multiple sclerosis (MS), inhibits the proliferation of lymphocytes. As a result, fewer lymphocytes that could damage the CNS pass through the blood-brain barrier. The efficacy and safety of teriflunomide in the global population were examined in the multinational randomized double-blind placebo-controlled TOWER study, with an interesting subanalysis published by Chinese authors.

Source: Multiple Sclerosis 24. 9. 2020

News Physical Activity in Young Men with Hemophilia A

What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.

Source: Hemophilia with Movement 6. 10. 2023

News Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment

In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy are available today. However, there is no clinical data comparing the risk of bleeding associated with physical activity between factor and non-factor treatments. In this situation, one approach is to model possible scenarios and attempt to indirectly compare different modalities of bleeding prevention.

Source: Hemophilia 18. 5. 2023

Články časopisu Prospective, multicentric, non-interventional study to assess the existing treatment of type 2 diabetes mellitus patients inadequately controlled with metformin monotherapy –⁠ KOMETA CZ

Author of the article: Š. Svačina, V. Veselá Source: Vnitřní lékařství | 12/2013 16. 12. 2013

Články časopisu Personalized medicine in haematooncology –⁠ the pathologist’s perspective

Author of the article: Vít Campr Source: Časopis lékařů českých | 10/2010 16. 10. 2010

News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations

Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.

Source: Diabetes 20. 12. 2021

News Brigatinib in the Therapy of ALK-Positive NSCLC –⁠ First Results of the J-ALTA Study

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.

Source: Non-Small Cell Lung Cancer 9. 9. 2021

News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC

As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.

Source: Colorectal Cancer 16. 6. 2020

News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?

A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?

Source: 27. 5. 2020

News Sports in People with Hemophilia –⁠ Possible and Safe

Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.

Source: Hemophilia with Movement 19. 6. 2023

News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies

This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.

Source: Hemophilia with Movement 19. 8. 2022

News Brief from ASH 2021: News and Advances in CLL Treatment

The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.

Source: Chronic Lymphocytic Leukemia 12. 4. 2022